Enhanced Stimulation of Anti-Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen

American Journal of Reproductive Immunology

Volumn 65, Issue 6, 2011, Pages 597-609

  Hanlon, Douglas J ^a   Aldo, Paulomi B ^a   Devine, Lesley ^a   Alvero, Ayesha B ^a   Engberg, Anna K ^a   Edelson, Richard ^a   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD8+ T cells; Dendritic cells; Nanoparticle; Ovarian cancer; Tumor antigens; Vaccine

Indexed keywords

NANOPARTICLE; POLYGLACTIN; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LYSATE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MONOCYTE; NANOENCAPSULATION; OVARY CANCER; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LACTIC ACID; LYMPHOCYTE ACTIVATION; NANOPARTICLES; OVARIAN NEOPLASMS; POLYGLYCOLIC ACID;

EID: 79955153739     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2010.00968.x     Document Type: Article

References (58)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Einhorn N: Ovarian cancer. Early diagnosis and screening. Hematol Oncol Clin North Am 1992; 6:843-850.
3. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, Hogdall CK, Goode EL, Sellers TA, Vierkant RA, Cunningham JC, Schildkraut JM, Berchuck A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Song H, Pharoah PD, Spurdle AB, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G: Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer 2009; 100:412-420.
4. Onnis A: The management of ovarian cancer: an update. Eur J Gynaecol Oncol 1997; 18:157-160.
5. Ozols RF: Chemotherapy for ovarian cancer. Semin Oncol 1999; 26:34-40.
6. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009; 8:158-166.
7. Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol 2009; 27:83-117.
8. Odunsi K, Sabbatini P: Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 2008; 59:62-74.
9. Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K: Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother 2008; 57:1185-1195.
10. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ: Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999; 73:5402-5410.
11. Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon MJ: Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Ginecol 2002; 54:133-144.
12. Cannon MJ, Santin AD, O'Brien TJ: Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004; 16:87-92.
13. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S: Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des 2005; 11:3485-3500.
14. Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ: Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res 2005; 11:3446-3454.
15. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T: Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002; 51:45-52.
16. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH: TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517-1527.
17. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000; 96:422-430.
18. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP: In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000; 183:601-609.
19. Zhao X, Wei YQ, Peng ZL: Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 2001; 30:33-45.
20. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96:3102-3108.
21. Shu S, Zheng R, Lee WT, Cohen PA: Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. Crit Rev Immunol 2007; 27:463-483.
22. Shu S, Cohen P: Tumor-dendritic cell fusion technology and immunotherapy strategies. J Immunother 2001; 24:99-100.
23. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ: Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006; 117:78-88.
24. Shen LF, Zhang YD, Shen HJ, Zeng S, Wang X, Wang C, Le Y, Shen H: Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice. Chin Med J (Engl) 2006; 119:1287-1293.
25. Ludewig B, Junt T, Hengartner H, Zinkernagel RM: Dendritic cells in autoimmune diseases. Curr Opin Immunol 2001; 13:657-662.
26. Ludewig B, Bonilla WV, Dumrese T, Odermatt B, Zinkernagel RM, Hengartner H: Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur J Immunol 2001; 31:1772-1779.
27. Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM: Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 2001; 166:3678-3687.
28. Greeneltch KM, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K, Abrams SI: Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Res 2007; 67:10406-10416.
29. Stewart TJ, Abrams SI: Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 2007; 179:2851-2859.
30. Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI: Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Rev Mol Med 2007; 9:1-20.
31. Lin ML, Zhan Y, Villadangos JA, Lew AM: The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol 2008; 86:353-362.
32. Bode U, Lorchner M, Ahrendt M, Blessenohl M, Kalies K, Claus A, Overbeck S, Rink L, Pabst R: Dendritic cell subsets in lymph nodes are characterized by the specific draining area and influence the phenotype and fate of primed T cells. Immunology 2008; 123:480-490.
33. Toyokawa H, Nakao A, Bailey RJ, Nalesnik MA, Kaizu T, Lemoine JL, Ikeda A, Tomiyama K, Papworth GD, Huang L, Demetris AJ, Starzl TE, Murase N: Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. Liver Transpl 2008; 14:346-357.
34. Scholl I, Boltz-Nitulescu G, Jensen-Jarolim E: Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Control Release 2005; 104:1-27.
35. Roth-Walter F, Scholl I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E: Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 2005; 23:2703-2710.
36. Kovacsovics-Bankowski M, Rock KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995; 267:243-246.
37. Grant EP, Michalek MT, Goldberg AL, Rock KL: Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol 1995; 155:3750-3758.
38. Demento S, Steenblock ER, Fahmy TM: Biomimetic approaches to modulating the T cell immune response with nano- and micro-particles. Conf Proc IEEE Eng Med Biol Soc 2009; 2009:1161-1166.
39. Demento SL, Eisenbarth SC, Foellmer HG, Platt C, Caplan MJ, Mark Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell RA, Fahmy TM: Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009; 27:3013-3021.
40. Brannon-Peppas L, Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56:1649-1659.
41. Waeckerle-Men Y, Gander B, Groettrup M: Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005; 109:35-46.
42. Waeckerle-Men Y, Groettrup M: PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005; 57:475-482.
43. Partidos CD, Vohra P, Jones D, Farrar G, Steward MW: CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles. J Immunol Methods 1997; 206:143-151.
44. Jones DH, Partidos CD, Steward MW, Farrar GH: Oral delivery of poly(lactide-co-glycolide) encapsulated vaccines. Behring Inst Mitt 1997; 98:220-228.
45. Ren JM, Zou QM, Wang FK, He Q, Chen W, Zen WK: PELA microspheres loaded H. pylori lysates and their mucosal immune response. World J Gastroenterol 2002; 8:1098-1102.
46. Solbrig CM, Saucier-Sawyer JK, Cody V, Saltzman WM, Hanlon DJ: Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol Pharm 2007; 4:47-57.
47. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G: Phenoxodiol-an isoflavon analogue-induces apoptosis in chemo-resistant ovarain cancer cells. Oncogene 2003; 22:2611-2620.
48. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G: Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene 2008; 27:4712-4723.
49. Chen R, Alvero AB, Silasi DA, Mor G: Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007; 57:93-107.
50. Jager E, Ringhoffer M, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F, Knuth A: Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res 1996; 6:419-425.
51. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F, Knuth A: Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996; 67:54-62.
52. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G: Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008; 27:225-233.
53. Mor G, Straszewski S, Kamsteeg M: Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. Biochem Pharmacol 2002; 64:1305.
54. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-240.
55. Kuo YR, Huang CW, Goto S, Wang CT, Hsu LW, Lin YC, Yang KD, Chen CL, Lee WP: Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation. J Surg Res 2009; 153:317-325.
56. Klarquist J, Barfuss A, Kandala S, Reust MJ, Braun RK, Hu J, Dilling DF, McKee MD, Boissy RE, Love RB, Nishimura MI, Le Poole IC: Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol 2009; 175:2463-2472.
57. Kaka AS, Shaffer DR, Hartmaier R, Leen AM, Lu A, Bear A, Rooney CM, Foster AE: Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother 2009; 32:726-736.
58. Michaeli Y, Denkberg G, Sinik K, Lantzy L, Chih-Sheng C, Beauverd C, Ziv T, Romero P, Reiter Y: Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J Immunol 2009; 182:6328-6341.